Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

COEP Income Before Tax

Profit after all operating and non-operating items but before income tax.

Coeptis Therapeutics, Inc.NASDAQ: COEP

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$4.02M, compared with -$3.42M a year earlier. Trailing-twelve-month income before tax was -$12.88M.

Context

  • Income before tax amounted to 900.7% of revenue in FY2025.
  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$4.02M or moves back toward the trailing-twelve-month quarterly average of -$3.22M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.02M-147.8% QoQ
Last fiscal yearDec 2025
-$12.28M-12.9% YoY
LTMMar 2026
-$12.88M-14.0% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.5%——
1 year-12.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(12.28M) USD
Year-over-year change
-12.9%

Income Before Tax vs competitors

How COEP compares with its peers on the latest reported figures

  • COEP's LTM Mar 2026 income before tax of -$12.88M is the 2nd highest of the 9 companies compared; the peer median is -$29.91M.
  • Its year-over-year change of -14.0% is the 4th highest of 9, against a peer median of -125.9%.
  • Income before tax amounts to 910.7% of revenue for COEP, versus a peer median of 599.6%.
COEP Competitors Peer median
Income Before Tax for COEP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026-$9.22M +26.3%——
COEPCoeptis Therapeutics, Inc.LTM Mar 2026-$12.88M -14.0%—910.7%
CUECue Biopharma, Inc.LTM Mar 2026-$19.02M +53.1%—58.1%
EQEquillium, Inc.LTM Mar 2026-$19.06M -39.8%——
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026-$24.54M -1.8%—1070.3%
OSTXOS Therapies IncorporatedLTM Mar 2026-$35.27M -212.1%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$62.51M -395.9%—18764.2%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$107.85M -435.1%——
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026-$194.96M -211.9%—129.0%
Peer median (excluding COEP) -$29.91M-125.9%—599.6%

Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75K0001.36M
Cost of Revenue0000180.63K
Gross Profit75K0001.18M
Gross Margin100.0%———86.7%
Research & Development020.89K6.67M2.33M1.28M
Selling, General & Admin14.12M34.18M13.82M6.72M11.95M
Operating Expenses14.12M34.2M21.49M10.05M14.23M
Depreciation & Amortization447.41K1M1.04M1.04M1.22M
EBITDA(12.81M)(36.35M)(20.12M)(9.38M)(10.41M)
EBITDA Margin-17086.3%———-763.9%
Operating Income(14.05M)(34.2M)(21.49M)(10.05M)(13.04M)
Operating Margin-18727.9%———-956.9%
Interest Income0000116.5K
Interest Expense187.13K218.41K107.69K396.12K642.38K
Other Income / Expenses596.65K(3.38M)224.59K(822.92K)766.31K
Income Before Tax(13.45M)(37.57M)(21.27M)(10.88M)(12.28M)
Pre-Tax Margin-17932.4%———-900.7%
Income Tax Expense00000
Net Income(13.45M)(37.57M)(21.27M)(10.68M)(11.92M)
Net Margin-17932.4%———-874.3%
EPS (Basic)(13.16)(2.87)(0.83)(5.65)(2.81)
EPS (Diluted)(13.16)(2.87)(0.83)(5.65)(2.81)
Weighted Avg Shares1.02M14.3M25.69M1.93M4.23M
Weighted Avg Shares (Diluted)1.02M14.3M25.69M1.93M4.23M

Coeptis Therapeutics, Inc.

NASDAQ:COEP

Intrinsic Alpha fair value

Locked

Current Price

$14.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.